" class="no-js "lang="en-US"> Univercells - Medtech Alert
Monday, August 11, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Univercells | Pharmtech Focus

Univercells

About Univercells

Univercells

Univercells is a global life sciences company making biologics available to everyone. We operate as a campus of start-ups: five businesses solving different parts of the same puzzle – meeting global demand for bioproduction. Because it is not enough for a drug to exist. To change the world it must be accessible to everyone.

Related Story

Industry News

 Univercells Acquires SynHelix

Univercells Acquires SynHelix, Entering into Synthetic Biology and the Race to Next-generation DNA Synthesis

January 6 2022

Univercells S.A. (Univercells) today announces its acquisition of SynHelix, a biotechnology company that aims to debottleneck […]